| Previous Close | 5.37 |
| Open | 5.35 |
| Bid | 5.20 x 200 |
| Ask | 10.00 x 100 |
| Day's Range | 5.32 - 5.42 |
| 52 Week Range | 4.79 - 10.80 |
| Volume | 302,339 |
| Avg. Volume | 524,312 |
| Market Cap | 307.15M |
| Beta | 1.28 |
| PE Ratio (TTM) | -1.24 |
| EPS (TTM) | -4.34 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.13 |
- Barrons.com•8 days ago
[$$] 4 Buys in a Watchful Market
Eli Lilly • LLY-NYSE Long-Term Buy • Price $82.17 on Sept. 12 by Hilliard Lyons At the European Society for Medical Oncology Annual Congress, Lilly presented strong data from a key trial on its cancer drug Abemaciclib. As a reminder to investors, while cross-trial comparisons are difficult to make, the presentation provided physicians and investors the best opportunity to compare Abemaciclib to the other CDK4/6 inhibitors, and we think it can take some market share from competitors in this niche.
- PR Newswire•12 days ago
Iconix Brand Group to Present at CL King's Best Ideas Conference 2017
NEW YORK , Sept. 11, 2017 /PRNewswire/ -- Iconix Brand Group, Inc. (Nasdaq: ICON) ("Iconix" or the "Company"), today announced that its Chief Financial Officer, Dave Jones is scheduled ...
Motley Fool•12 days agoWhy Iconix Brand Group Inc. Stock Lost 16% in August
The consumer-products specialist surprised investors with weak second-quarter results.
